Credit Suisse strategist Neelkanth Mishra said India still has scope for meaningful policy easing, arguing that the repo rate could fall to a decade low over the coming quarters. He also flagged December as a potential inflection point for a broader market pickup that could support equity indices.
"Neelkanth Mishra Sees Room for Meaningful Rate Cuts as Repo Could Hit Decade Low"
Credit Suisse strategist Neelkanth Mishra said India still has scope for meaningful policy easing, arguing that the repo rate could fall to a decade low over the coming quarters. He also flagged December as a potential inflection point for a broader market pickup that could support equity indices.
Neelkanth Mishra Sees Room for Meaningful Rate Cuts as Repo Could Hit Decade Low
RDU Global Wire
Markets, IPOs & Wealth Desk
Credit Suisse strategist Neelkanth Mishra said India still has scope for meaningful policy easing, arguing that the repo rate could fall to a decade low over the coming quarters. He also flagged December as a potential inflection point for a broader market pickup that could support equity indices.
Editorial & Verification Notice
Reported by RDU Global Correspondent. Formatted and verified using real-time institutional and journalistic wire feeds. Independent reporting adhering to the RDU Global Editorial Code of Conduct.
Related Coverage
Tata Steel Shares in Focus as Investors Reassess Cyclical Risk and India’s Industrial Outlook
Tata Steel’s stock remains a closely watched barometer for India’s industrial cycle, with investors tracking how global steel prices, domestic demand, and margin trends shape the company’s valuation. The share’s history reflects the market’s shifting view of commodities, capital spending, and the broader macroeconomic backdrop in India.
Sun Pharma Shares Under Spotlight as Investors Track Price History, Valuation Signals and Sector Momentum
Sun Pharmaceutical Industries Ltd. remains in focus as investors reassess its share-price trajectory against a broader backdrop of Indian equity market volatility, healthcare demand resilience and sector rotation. Market participants are watching whether the stock’s long-term performance can continue to justify its premium positioning in a changing macroeconomic environment. The latest attention around Sun Pharma underscores how blue-chip pharmaceutical names are being evaluated not only on earnings durability, but also on valuation discipline, export exposure and domestic policy sensitivity.
Pixel Launch Raises Fresh Questions Over Google Assistant’s AI and User Privacy
Google’s latest Pixel launch has renewed scrutiny over how deeply artificial intelligence can observe, learn from, and anticipate user behavior. While the company is positioning AI as a convenience layer for everyday tasks, the broader debate is shifting toward data security, consent, and the limits of surveillance by design.
